🔎 Trials Near Me

Hem › Kronisk lymfatisk leukemi › Pennsylvania

Kliniska studier för Kronisk lymfatisk leukemi i Pennsylvania

22 studier för Kronisk lymfatisk leukemi söker deltagare vid platser i Pennsylvania.

Städer i Pennsylvania

Officiell studietext (engelska)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Geisinger Medical Center, Danville
  • Thomas Jefferson University Hospital, Philadelphia
  • Jefferson Torresdale Hospital, Philadelphia
  • och 1 fler
RekryterarFas 3
Ålder 65 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • och 7 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • och 4 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Penn State Milton S Hershey Medical Center, Hershey
  • Thomas Jefferson University, Philadelphia
  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06943872

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07277231

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall
  • Cancer Care Associates Of York ( Site 0005), York
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • UPMC Hillman Cancer Center, Pittsburgh
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • UPMC Hillman Cancer Center, Pittsburgh
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 11 sep. 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Philadelphia
  • Research Site, Pittsburgh
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT06564038

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 28 aug. 2026 · NCT07520006

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • UPMC Hillman Cancer Center, Pittsburgh
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 11 aug. 2026 · NCT07342478

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 2 juli 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 12 juni 2026 · NCT07271667

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Cancer Care Associates Of York, York
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 19 maj 2026 · NCT06588478

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • University of Pennsylvania Hospital, Philadelphia
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 2 mars 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • University of Pennsylvania Hospital, Philadelphia
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 2 mars 2026 · NCT06876649

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • Pennsylvania Oncology Hematolo /ID# 249637, Philadelphia
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 9 feb. 2026 · NCT04895436

Two Step Haplo With Radiation Conditioning

  • Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 30 okt. 2025 · NCT05031897

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

  • AHN Cancer Institute - West Penn Hospital, Pittsburgh
RekryterarFas 2
Ålder 18 till 79 · Alla kön · Uppdaterad 13 jan. 2025 · NCT05281809

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.